华法林对围产期心肌病抗凝治疗的临床观察

目的通过对比接受华法林治疗3个月与6个月时的临床效果，以探讨华法林对围产期心肌病患者的影响。方法选择2010年12月-2012年12月住院的42例围产期心肌病患者作为研究对象．按照入院顺序将上述患者随机分为两组．两组患者均予以抗心力衰竭治疗，20例（A组）使用华法林治疗3个月，22例（B组）使用华法林治疗6个月，调整华法林剂量将国际标准化比值维持在2．0～3．0，观察比较两组血浆D-二聚体、深静脉血栓和出血率。结果两组治疗后D-二聚体水平显著下降，B组的下降效果明显好于A组，随访发现B组的深静脉血栓形成率明显低于A组，两组出血率比较不存在显著性差异。结论华法林对围产期心肌病抗凝效果明显。持续治疗时间可能是影响抗凝效果的重要因素。

Clinical Observation of Warfarin in Anticoagulant Treatment for Peripar- tum Cardiomyopathy

Objective By contrast when receiving warfarin therapy for three months and six months clinical results to study the effects of warfarin for patients with peripartum eardiomyopathy in. Methods 42 inpatients with peripartum eardiomyopathy from December 2010 to December 2012 were chosen as research objects and according to admission order randomly divided into 2 groups. Both groups were given anti-heart failure treatments. 20 cases （A group） were given warfarin for 3 months and 22 cases （B group） were given warfarin for 6 months. International normalized ratio of warfarin dosage was regulated and kept as 2.0-3.0. Plasma D-dimer, deep vein thrombosis and bleeding rate of the 2 groups were observed and compared. Results After treatment, D-dimer levels of the 2 groups both dropped significantly and the drop effect of B group was obviously better than A group. By follow-up visits, deep vein thrombosis rate of B group was obviously lower than A group. No significant difference existed between bleeding rates of the 2 groups. Conclusion Warfarin has an obvious effect in anticoagulant treatment for peripartum cardiomyopa- thy, and the duration of treatment may be an important factor that influences anticoagulant effect.